CardieX Ltd (ASX:CDX) subsidiary ATCOR has been granted a new patent by the European Patent Office (EPO) to protect the intellectual property (IP) for the company’s proprietary SphygmoCor technology used in cuff-based blood pressure devices.
EPO Patent Number EP2566387 further protects the company’s IP in relation to the measurement of a whole central blood pressure waveform with cardiovascular features using a brachial cuff.
Shares have been as much as 24% higher to 6 cents intra-day and have climbed from 2 cents at the market close on June 29.
Examining officers from the EPO specifically referenced the substantial differences in respect of any other existing patents when granting the new patent to ATCOR, demonstrating the unique nature of the technology.
CardieX CEO and managing director Craig Cooper said: “We are very pleased to be granted this new patent to protect our IP in Europe.
“Of great significance is the findings of the examining officers from the EPO which were similar to the findings we received from examiners in the US in 2016 - that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology.”
Patent EP2566387 specifically covers non-invasively estimating the heart’s pressure and pressure waveform with features related to cardiac function and arterial properties using a conventional BP cuff inflated to low pressure.
The patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease which otherwise would require an invasive procedure.
The granting of the European patent follows similar patents already granted to the company in the United States and Japan with the new European patent in force until 2034.